Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Post by lonc17on Dec 09, 2023 6:02pm
350 Views
Post# 35776508

Options

OptionsI just noticed on SEDI that there are numerous options expriing on Monday, December 11, 2023.

They were all issued ten years ago and they have a strike price of $1.74 CDN.
They are in the money as of close on Friday, December 9th.

Alan Warrander 16,000
G. Van Amersfoort 30,000
Alan Tuchman 55,000
Brad Thompson 360,000
Fred Stewart 45,000
Robert Schultz 60,000
Kirk Look 160,000
John Leivonen 35,000
Edwin Levy 30,000
George McGill 80,000
James Dinning 35,000
Mary Ann Dillahunty 40,000
Matt Coffey 240,000

We can expect some on the list to excercise their options on Monday morning and likely sell the shares to pocket some small amount of extra cash for Christmas.
For example, George McGill could exercise at $1.74 and then sell 80,000 shares immediately for $1.90 and net $12,800 for his troubles.

Others with smaller amounts may simply have forgotten about these options or will not bother and let them expire since the difference between strick price and close on Monday will be inconsequential. Especially if they all intend on selling Monday in which case the share price will likely drop below strike.

Brad Thompson may not even hold these options anymore due to the unusual circumstances surrounding his departure from the company.

MC and KL will be crossing their fingers and hoping like hell the share price drops below $1.74 CDN on Monday to save them the expense and future loss from having to convert and hold shares.

Note, these numbers are in addition to the 175,000 options MC has that expire on Wednesday, December 13 and have a strike price of $1.45.

So by Wednesday, MC could be the proud (and sorry) owner of 415,000 newly minted ONC shares that will have cost him about $671,000... more than half his annual wage.

I don't give a damn what most on this list do with their options and resulting shares. But if MC or KL choose not to exercise, or do excerise but then sell, then everyone should take is as a clear message that ONC is headed for a long, sad downward spiral to oblivion.


<< Previous
Bullboard Posts
Next >>